Literature DB >> 17466790

Outcome of a comprehensive follow-up program to enhance maturation of autogenous arteriovenous hemodialysis access.

Robert B McLafferty1, Raymond W Pryor, Colleen M Johnson, Don E Ramsey, Kim J Hodgson.   

Abstract

OBJECTIVE: To examine the outcome of a comprehensive follow-up program for autogenous arteriovenous hemodialysis access (AVF) when performed by the hemodialysis access surgeon.
METHODS: Patients with first time AVFs between 2000 and 2005 underwent history and physical examination between the third and sixth postoperative weeks, followed by repeat examination every 6 to 8 weeks until maturation. Primary outcomes included maturation assessment and interventions required prior to maturation. Maturation was defined as 4 consecutive weeks of sustainable AVF hemodialysis access.
RESULTS: One hundred thirteen patients had 113 AVFs. Mean age was 64 years (range: 26-94) and 52% were male. AVFs included 8 (7%) radiocephalic, 90 (80%) brachiocephalic, and 15 (13%) basilic vein transposition. Overall, the maturation rate was 72% (failure rate of 28%). Excluding deaths and transplants prior to maturation, the maturation rate was 82% (failure rate 18%). Eighty-three (73%) patients had no intervention prior to maturation and 30 (27%) required intervention. There was no significant difference in failure rate between AVFs not requiring an intervention (13 of 83, 15%) and those requiring intervention (5 of 30, 16%). For AVFs requiring intervention, 23 (61%) patients had an endovascular intervention and 15 (39%) an operative intervention. One intervention was performed in 64%, two in 24%, and three in 12%. Ninety-three percent of AVFs having an endovascular intervention matured compared with 60% having operative intervention (P = .10). AVFs requiring intervention had a maturation time (mean: 35 weeks, range: 10-54) that was significantly longer (P = .003) than those without (mean 11 weeks, range: 6-35).
CONCLUSIONS: With a surgeon directed comprehensive follow-up program to assess AVF maturation, a large proportion (30 of 43, 69%) of AVFs with a problem were detected. Of those identified, most (25 of 30, 83%) could be salvaged to maturation with intervention. The Kidney and Dialysis Outcome Quality Initiative (K/DOQI) should consider incorporating a comprehensive follow-up program into its guidelines.

Entities:  

Mesh:

Year:  2007        PMID: 17466790     DOI: 10.1016/j.jvs.2007.01.013

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

Review 1.  New Insights into Dialysis Vascular Access: What Is the Optimal Vascular Access Type and Timing of Access Creation in CKD and Dialysis Patients?

Authors:  Karen Woo; Charmaine E Lok
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-11       Impact factor: 8.237

2.  Effect of local papaverine on arteriovenous fistula maturation in patients with end-stage renal disease.

Authors:  Gholamreza Kazemzadeh; Ali Saberi; Reza Manani; Fatemeh Sadeghipour; Asghar Rahmani
Journal:  J Bras Nefrol       Date:  2019-04-11

Review 3.  [Placement of a native arteriovenous access].

Authors:  T Schmitz-Rixen; M Meyn; V Mickley
Journal:  Chirurg       Date:  2012-09       Impact factor: 0.955

4.  Arteriovenous Access Failure, Stenosis, and Thrombosis.

Authors:  Jennifer M MacRae; Christine Dipchand; Matthew Oliver; Louise Moist; Charmaine Lok; Edward Clark; Swapnil Hiremath; Joanne Kappel; Mercedeh Kiaii; Rick Luscombe; Lisa M Miller
Journal:  Can J Kidney Health Dis       Date:  2016-09-27

5.  Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study.

Authors:  Michael Allon; Peter B Imrey; Alfred K Cheung; Milena Radeva; Charles E Alpers; Gerald J Beck; Laura M Dember; Alik Farber; Tom Greene; Jonathan Himmelfarb; Thomas S Huber; James S Kaufman; John W Kusek; Prabir Roy-Chaudhury; Michelle L Robbin; Miguel A Vazquez; Harold I Feldman
Journal:  Am J Kidney Dis       Date:  2018-02-02       Impact factor: 8.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.